美國州份檢察長與藥廠及分銷商就鴉片成分藥成癮危機達260億美元和解
美國州份檢察長與美國三大藥物分銷商McKesson(MCK.US)、Cardinal Health(CAH.US)及AmerisourceBergen(ABC.US),與及藥物生產商強生(JNJ.US),就含鴉片成分藥物氾濫達成260億美元和解協議,有關協議須經州政府同意下才能落實。
其中強生支付50億美元,分9年繳付,當中37億美元須在3年內繳付。McKesson支付79億美元,Cardinal Health及AmerisourceBergen各支付64億美元,款項在18年內清付。有關款項料用作戒除藥癮、家庭支援教育及其他社會項目。約22億美元將用作支付法庭訴訟成本。協議須有最少48個州的政府支持才生效。
各州將有30日時間檢視協議。北卡羅萊納州檢察長Josh Stein預期將有遠超過40個州份最終簽字。跑易斯安那州檢察長Jeff Landry指不簽字州份將爲不負責任,並指不要因爲追求完美淪爲做好事的敵人。
鴉片成分藥成癮危機自1999年以來導致十萬計美國人因過量服用藥物死亡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.